Results 31 to 40 of about 34,432 (188)

Control Intervention Strategies for Within-Host, Between-Host and their Efficacy in the Treatment, Spread of COVID-19 : A Multi Scale Modeling Approach [PDF]

, 2020
The COVID-19 pandemic has resulted in more than 14.5 million infections and 6,04,917 deaths in 212 countries over the last few months. Different drug intervention acting at multiple stages of pathogenesis of COVID-19 can substantially reduce the infection induced,thereby decreasing the mortality.
arxiv   +1 more source

Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing

Pharmaceutics, 2020
Remdesivir exhibits in vitro activity against SARS-CoV-2 and was granted approval for emergency use. To maximize delivery to the lungs, we formulated remdesivir as a dry powder for inhalation using thin film freezing (TFF).
Sawittree Sahakijpijarn, Chaeho Moon, John J. Koleng, Dale J. Christensen, Robert O. Williams   +4 more
doaj   +1 more source

Machine Learning for Real-World Evidence Analysis of COVID-19 Pharmacotherapy [PDF]

arXiv, 2021
Introduction: Real-world data generated from clinical practice can be used to analyze the real-world evidence (RWE) of COVID-19 pharmacotherapy and validate the results of randomized clinical trials (RCTs). Machine learning (ML) methods are being used in RWE and are promising tools for precision-medicine.
arxiv  

Treatment effect of remdesivir on the mortality of hospitalised COVID-19 patients in Switzerland across different patient groups: a tree-based model analysis

Swiss Medical Weekly, 2023
AIMS OF THE STUDY: Remdesivir has shown benefits against COVID-19. However, it remains unclear whether, to what extent, and among whom remdesivir can reduce COVID-19-related mortality. We explored whether the treatment response to remdesivir differed by
Janne Estill, Plamenna Venkova-Marchevska, Huldrych F. Günthard, Sara Botero-Mesa, Amaury Thiabaud, Maroussia Roelens, Laure Vancauwenberghe, Lauro Damonti, Ulrich Heininger, Anne Iten, Peter W. Schreiber, Rami Sommerstein, Sarah Tschudin-Sutter, Nicolas Troillet, Danielle Vuichard-Gysin, Andreas Widmer, Torsten Hothorn, Olivia Keiser   +17 more
doaj   +1 more source

The utility of remdesivir in SARS-CoV-2: A single tertiary care center experience from a developing country

Exploratory Research in Clinical and Social Pharmacy, 2022
Background: Remdesivir is a monophosphoramidate prodrug of an adenosine analog, and it has a broad-spectrum antiviral activity against paramyxoviruses, flaviviruses, and coronaviruses.
Muhammad Irfan Malik, Sardar Al Fareed Zafar, Muna Malik, Fabiha Qayyum, Iqra Akram, Ammarah Arshad, Khalid Waheed, Jodat Saleem, Abdul Jabbar, Muhammad Junaid Tahir, Zohaib Yousaf   +10 more
doaj  

Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study

Infectious Diseases and Therapy, 2023
Introduction In the PINETREE study, early remdesivir treatment reduced risk of coronavirus disease 2019 (COVID-19)-related hospitalizations or all-cause death versus placebo by 87% by day 28 in high-risk, non-hospitalized patients. Here we report results
Samuel M. Brown, Morgan J. Katz, Adit A. Ginde, Kavita Juneja, Monica Ramchandani, Joshua T. Schiffer, Carlos Vaca, Robert L. Gottlieb, Yuan Tian, Emon Elboudwarej, Joshua A. Hill, Richard Gilson, Lauren Rodriguez, Charlotte Hedskog, Shuguang Chen, Jairo M. Montezuma-Rusca, Anu Osinusi, Roger Paredes   +17 more
doaj   +1 more source

The effect of remdesivir on selective biomarkers and its value in predicting the clinical outcome in patients with COVID-19

Asian Journal of Medical Sciences, 2021
Background: To the best of our knowledge, there have been no studies to evaluate the effect of remdesivir on inflammatory markers. Aims and Objectives: To study the effect of Remdesivir on Selective biomarkers namely C-Reactive Protein (CRP), Lactate ...
Sanjana Rai , Dyna Jones , Chinnappa Anjanappa Jayashankar , Venkata Bharat Kumar Pinnelli , Eashwer Manpreeth , Venkata Sai Raghava Prashanthi Seetha   +5 more
doaj   +1 more source

Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study

Scientific Reports, 2022
Remdesivir has been shown to reduce recovery time and mortality among patients with coronavirus disease 2019 (COVID-19). However, data regarding the efficacy and safety of remdesivir use are limited in Japan.
Kazuhito Miyazaki, Yukihiro Yoshimura, Nobuyuki Miyata, Hiroaki Sasaki, Aya Shiba, Masaharu Aga, Yusuke Hamakawa, Yuri Taniguchi, Yuki Misumi, Yoko Agemi, Tsuneo Shimokawa, Hiroaki Okamoto, Natsuo Tachikawa   +12 more
doaj   +1 more source

Evidence Aggregation for Treatment Choice [PDF]

arXiv, 2021
Consider a planner who has limited knowledge of the policy's causal impact on a certain local population of interest due to a lack of data, but does have access to the publicized intervention studies performed for similar policies on different populations.
arxiv  

Optimal Drug Regimen and Combined Drug Therapy and its Efficacy in the Treatment of COVID-19 : An Within-Host Modeling Study [PDF]

, 2020
The COVID-19 pandemic has resulted in more than 30.35 million infections and 9, 50, 625 deaths in 212 countries over the last few months. Different drug intervention acting at multiple stages of pathogenesis of COVID-19 can substantially reduce the infection induced mortality. The current within-host mathematical modeling studies deals with the optimal
arxiv   +1 more source